{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:38:13Z","timestamp":1790645893272,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0005527","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000}}],"reference-count":74,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["ME065067"],"award-info":[{"award-number":["ME065067"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0005527","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T13:23:45Z","timestamp":1494595425000},"page":"e0005527","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":148,"title":["A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH"],"prefix":"10.1371","volume":"11","author":[{"given":"Mohamed","family":"Osman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Keding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-3094","authenticated-orcid":true,"given":"Rhian","family":"Gabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8332-7196","authenticated-orcid":true,"given":"Sarah","family":"Forrester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Colloca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Siani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Aebischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8796-4755","authenticated-orcid":true,"given":"Paul M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"J Alvar","year":"2012","journal-title":"PloS one"},{"issue":"Suppl 2","key":"ref2","doi-asserted-by":"crossref","first-page":"B244","DOI":"10.1016\/j.vaccine.2012.11.080","article-title":"Case study for a vaccine against leishmaniasis","volume":"31","author":"J Alvar","year":"2013","journal-title":"Vaccine"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"892817","DOI":"10.1155\/2012\/892817","article-title":"Development of Vaccines against Visceral Leishmaniasis","volume":"2012","author":"KJ Evans","year":"2012","journal-title":"Journal of tropical medicine"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/j.1469-0691.2011.03610.x","article-title":"Visceral leishmaniasis: immunology and prospects for a vaccine","volume":"17","author":"PM Kaye","year":"2011","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0035-9203(03)90093-9","article-title":"Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990\u201399","volume":"97","author":"J Convit","year":"2003","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-4362.2002.01336.x","article-title":"Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial","volume":"41","author":"J Machado-Pinto","year":"2002","journal-title":"International journal of dermatology"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trstmh.2007.08.006","article-title":"Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment","volume":"102","author":"AM Musa","year":"2008","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1371\/journal.pntd.0000943","article-title":"Vaccines for the leishmaniases: proposals for a research agenda","volume":"5","author":"CH Costa","year":"2011","journal-title":"PLoS neglected tropical diseases"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/eri.10.64","article-title":"Immunomodulators: use in combined therapy against leishmaniasis","volume":"8","author":"JE Dalton","year":"2010","journal-title":"Expert review of anti-infective therapy"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1756-3305-6-196","article-title":"Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27\u201329 June 2012","volume":"6","author":"P Desjeux","year":"2013","journal-title":"Parasites & vectors"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-9292-6-7","article-title":"Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis","volume":"6","author":"H Ghalib","year":"2007","journal-title":"Kinetoplastid biology and disease"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jir842","article-title":"Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis","volume":"205","author":"A Maroof","year":"2012","journal-title":"The Journal of infectious diseases"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trstmh.2009.07.026","article-title":"Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration","volume":"104","author":"AM Musa","year":"2010","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/trstmh\/trv039","article-title":"Development of Leishmania vaccines in the era of visceral leishmaniasis elimination","volume":"109","author":"CR Engwerda","year":"2015","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrmicro2608","article-title":"Leishmaniasis: complexity at the host-pathogen interface","volume":"9","author":"P Kaye","year":"2011","journal-title":"Nature reviews Microbiology"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"e0004415","DOI":"10.1371\/journal.pntd.0004415","article-title":"Combined Immune Therapy for the Treatment of Visceral Leishmaniasis","volume":"10","author":"RJ Faleiro","year":"2016","journal-title":"PLoS neglected tropical diseases"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/infdis\/jit401","article-title":"CD8 T cell exhaustion in human visceral leishmaniasis","volume":"209","author":"S Gautam","year":"2014","journal-title":"The Journal of infectious diseases"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"e1000431","DOI":"10.1371\/journal.ppat.1000431","article-title":"B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections","volume":"5","author":"T Joshi","year":"2009","journal-title":"PLoS pathogens"},{"issue":"1\u20133","key":"ref19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12026-009-8135-4","article-title":"Immune evasive mechanisms contributing to persistent Leishmania donovani infection","volume":"47","author":"S Stager","year":"2010","journal-title":"Immunologic research"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fimmu.2012.00005","article-title":"CD8(+) T cells in leishmania infections: friends or foes?","volume":"3","author":"S Stager","year":"2012","journal-title":"Frontiers in immunology"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00281-015-0475-7","article-title":"CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly","volume":"37","author":"FO Novais","year":"2015","journal-title":"Seminars in immunopathology"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1128\/IAI.74.1.773-776.2006","article-title":"Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen","volume":"74","author":"R Polley","year":"2006","journal-title":"Infection and immunity"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/nm933","article-title":"Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses","volume":"9","author":"S Stager","year":"2003","journal-title":"Nature medicine"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","article-title":"Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis","volume":"165","author":"S Stager","year":"2000","journal-title":"J Immunol"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","article-title":"Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis","volume":"174","author":"R Basu","year":"2005","journal-title":"J Immunol"},{"issue":"234","key":"ref26","doi-asserted-by":"crossref","first-page":"234ra56","DOI":"10.1126\/scitranslmed.3008222","article-title":"Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis","volume":"6","author":"S Das","year":"2014","journal-title":"Science translational medicine"},{"issue":"22","key":"ref27","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1016\/j.vaccine.2006.03.005","article-title":"Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani","volume":"24","author":"R Gamboa-Leon","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"e2853","DOI":"10.1371\/journal.pntd.0002853","article-title":"Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen","volume":"8","author":"G Grimaldi Jr.","year":"2014","journal-title":"PLoS neglected tropical diseases"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/jid.2009.393","article-title":"Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis","volume":"130","author":"S Ganguly","year":"2010","journal-title":"The Journal of investigative dermatology"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10875-015-0215-8","article-title":"Decreased Frequency and Secretion of CD26 Promotes Disease Progression in Indian Post Kala-azar Dermal Leishmaniasis","volume":"36","author":"S Mukherjee","year":"2016","journal-title":"Journal of clinical immunology"},{"issue":"35","key":"ref31","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1016\/j.vaccine.2009.05.084","article-title":"Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis","volume":"27","author":"S Noazin","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.vaccine.2011.11.005","article-title":"The development and clinical evaluation of second-generation leishmaniasis vaccines","volume":"30","author":"MS Duthie","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"GA O'Hara","year":"2012","journal-title":"The Journal of infectious diseases"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"SH Sheehy","year":"2012","journal-title":"PloS one"},{"key":"ref35","article-title":"ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans","author":"SH Sheehy","year":"2012","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"SH Sheehy","year":"2011","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"RD Antrobus","year":"2014","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial","volume":"16","author":"MD Tapia","year":"2016","journal-title":"The Lancet infectious diseases"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"AM Newman","year":"2015","journal-title":"Nature methods"},{"issue":"115","key":"ref40","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"E Barnes","year":"2012","journal-title":"Science translational medicine"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"O De Santis","year":"2016","journal-title":"The Lancet infectious diseases"},{"issue":"17","key":"ref42","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"K Ewer","year":"2016","journal-title":"The New England journal of medicine"},{"key":"ref43","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine\u2014Preliminary Report","author":"T Rampling","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"KM Quinn","year":"2015","journal-title":"The Journal of clinical investigation"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.3328","article-title":"Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events","volume":"17","author":"O Sobolev","year":"2016","journal-title":"Nature immunology"},{"issue":"50","key":"ref46","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"DE Zak","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.immuni.2008.05.012","article-title":"A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus","volume":"29","author":"D Chaussabel","year":"2008","journal-title":"Immunity"},{"issue":"2","key":"ref48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"S Li","year":"2014","journal-title":"Nature immunology"},{"issue":"19","key":"ref49","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2011.02.096","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis","volume":"29","author":"J Chakravarty","year":"2011","journal-title":"Vaccine"},{"issue":"9","key":"ref50","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"RN Coler","year":"2007","journal-title":"Infection and immunity"},{"issue":"46","key":"ref51","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2010.08.092","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis","volume":"28","author":"A Llanos-Cuentas","year":"2010","journal-title":"Vaccine"},{"issue":"40","key":"ref52","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1016\/j.vaccine.2010.07.063","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis","volume":"28","author":"E Nascimento","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"ref53","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"RN Coler","year":"2015","journal-title":"Clinical & translational immunology"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/trstmh\/trw016","article-title":"TB vaccine development and the End TB Strategy: importance and current status","volume":"110","author":"HA Fletcher","year":"2016","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.vaccine.2012.12.042","article-title":"Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery","volume":"31","author":"J Meyer","year":"2013","journal-title":"Vaccine"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1128\/IAI.00944-07","article-title":"Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13","volume":"75","author":"R Basu","year":"2007","journal-title":"Infection and immunity"},{"issue":"9","key":"ref57","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/513439","article-title":"HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages","volume":"195","author":"R Basu","year":"2007","journal-title":"The Journal of infectious diseases"},{"issue":"3","key":"ref58","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1128\/IAI.02404-14","article-title":"Protective and Pathological Functions of CD8+ T Cells in Leishmania braziliensis Infection","volume":"83","author":"TM Cardoso","year":"2015","journal-title":"Infection and immunity"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever","volume":"6","author":"GM Warimwe","year":"2016","journal-title":"Scientific reports"},{"issue":"39","key":"ref60","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1016\/j.vaccine.2010.12.056","article-title":"Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques","volume":"29","author":"V Kulkarni","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.gt.3300811","article-title":"Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy","volume":"6","author":"P de Felipe","year":"1999","journal-title":"Gene therapy"},{"issue":"7","key":"ref62","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"PF Robbins","year":"2011","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"10","key":"ref63","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1128\/CVI.00237-09","article-title":"A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire","volume":"16","author":"FA Mir","year":"2009","journal-title":"Clinical and vaccine immunology: CVI"},{"issue":"10","key":"ref64","doi-asserted-by":"crossref","first-page":"e008748","DOI":"10.1136\/bmjopen-2015-008748","article-title":"Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults","volume":"5","author":"CA Green","year":"2015","journal-title":"BMJ open"},{"issue":"6","key":"ref65","doi-asserted-by":"crossref","first-page":"e0128714","DOI":"10.1371\/journal.pone.0128714","article-title":"Pathogen-Specific T Cell Polyfunctionality Is a Correlate of T Cell Efficacy and Immune Protection","volume":"10","author":"A Boyd","year":"2015","journal-title":"PloS one"},{"issue":"7","key":"ref66","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"PA Darrah","year":"2007","journal-title":"Nature medicine"},{"issue":"10","key":"ref67","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"S Sridhar","year":"2013","journal-title":"Nature medicine"},{"issue":"3","key":"ref68","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.coi.2012.03.010","article-title":"Identifying gnostic predictors of the vaccine response","volume":"24","author":"WN Haining","year":"2012","journal-title":"Current opinion in immunology"},{"issue":"1","key":"ref69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/COH.0b013e32834dc37b","article-title":"Systems vaccinology: its promise and challenge for HIV vaccine development","volume":"7","author":"HI Nakaya","year":"2012","journal-title":"Current opinion in HIV and AIDS"},{"issue":"1","key":"ref70","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"TD Querec","year":"2009","journal-title":"Nature immunology"},{"issue":"3","key":"ref71","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines4030027","article-title":"Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection","volume":"4","author":"L Swadling","year":"2016","journal-title":"Vaccines"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s13071-016-1721-0","article-title":"The immunology of post-kala-azar dermal leishmaniasis (PKDL)","volume":"9","author":"EE Zijlstra","year":"2016","journal-title":"Parasites & vectors"},{"issue":"7632","key":"ref73","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"EN Borducchi","year":"2016","journal-title":"Nature"},{"issue":"3","key":"ref74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4269\/ajtmh.2012.10-0415","article-title":"The economic value of a visceral leishmaniasis vaccine in Bihar state, India","volume":"86","author":"BY Lee","year":"2012","journal-title":"The American journal of tropical medicine and hygiene"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0005527","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0005527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T19:35:44Z","timestamp":1540236944000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0005527"}},"subtitle":[],"editor":[{"given":"Mary Ann","family":"McDowell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":74,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0005527","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0005527","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]}}}